logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
N

Nadia Harbeck

LMU University Hospital
H指数:131
被引数:8.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting

在真实世界环境中，接受过内分泌疗法和细胞周期依赖性激酶抑制剂治疗的ER阳性、HER2阴性、<em>ESR1</em>突变转移性乳腺癌患者中elacestrant的疗效

ESMO Open
IF8.3
2026-09-140
OAAI
G. Curigliano; M. De Laurentiis; N. Harbeck; S. Kuemmel; J.Á. García-Sáenz; R. Sanchez Bayona; D. Rea; A. Okines; B. Pistilli; E. Sears; J. Maitland; S. Kloss; T. Wasserman; M. Ignatiadis
Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer: a phase 3 randomized controlled trial (NATALEE)

来曲唑联合非甾体芳香化酶抑制剂在HR+/HER2−早期乳腺癌中的安全性和治疗持续时间：一项Ⅲ期随机对照试验（NATALEE）

Breast Cancer Research
IF5.6
2026-08-040
OAAI
H. S. Rugo; N. Harbeck; G. N. Hortobagyi; J. O’Shaughnessy; C.-S. Huang; M. Martin; D. Juric; B. Pistilli; B. Xu; M. De Laurentiis; M. Untch; K. Afenjar; M. Gao; Z. Li; N. Bolotova; S. Waters; C. Barrios
A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2− Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence

CDK 4/6抑制剂在HR+/HER2−晚期/转移性乳腺癌一线治疗中的有效性：真实世界证据的系统文献综述

Cancers
IF4.4
2026-07-230
OA
Timothy Pluard; Thomas Grinda; Rodrigo Dienstmann; Marc Thill; Beata Korytowsky; Connie Chen; Sofiya Portuhay; Elizabeth M. Salvo-Halloran; Imtiaz A. Samjoo; Nadia Harbeck
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding “Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer” by Chen et al.

两种试验的故事：TAILORx和PlanB。关于Chen等人撰写的“基因组高风险、淋巴结阴性、HR阳性/HER2阴性乳腺癌中蒽环类药物的影响”一文的致编辑函。

Annals of Oncology
IF65.4
2025-12-200
PRE
Oleg Gluz; Ronald Kates; Sherko Kuemmel; Ulrike Nitz; Nadia Harbeck
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors

ESMO-ESTRO关于将放射治疗与CDK4/6、HER2、PARP或mTOR抑制剂联合应用的安全性共识声明

Radiotherapy and Oncology
IF5.3
2025-12-110
OAAI
Evert S.M. van Aken; Ajeet Kumar Gandhi; Sean M. O’Cathail; Gerben Borst; Jorge Barriuso; Emmanouil Fokas; Luis Castelo-Branco; Anne Hansen Ree; Evandro de Azambuja; Stephanie Kroeze; Ilaria Colombo; Antonin Levy; Carmen Criscitiello; Maximilian Niyazi; Nadia Harbeck; Ewa Szutowicz; Gabor Liposits; Marcel Verheij; Isabelle Ray-Coquard; Paolo Tarantino
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry

激素受体阳性早期乳腺癌患者参与WSG PlanB试验并在基因表达分析预筛选后的长期结局数据：WSG PlanB登记研究的10年生存结果

ESMO Open
IF8.3
2025-11-270
OAAI
U. Nitz; M. Graeser; O. Gluz; S. Kümmel; M. Just; C. Jackisch; C. zu Eulenburg; M. Christgen; N. Harbeck
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer

RNA表达特征与复发基因组改变的整合分析：治疗前与绝经状态、短期内分泌治疗反应及无病生存期的关联性研究（在腔面乳腺癌中）

ESMO Open
IF8.3
2025-11-210
OAAI
G. Zhang; H. Ni; L. Mishieva; S. Bartels; M. Christgen; H. Christgen; L.D. Kandt; M. Raap; R.E. Kates; O. Gluz; M. Graeser; S. Kümmel; U. Nitz; C. Plass; U. Mansmann; C. zu Eulenburg; C. Gerhäuser; H.H. Kreipe; N. Harbeck
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial

新辅助曲妥珠单抗德鲁替康单药或序贯多西他赛、曲妥珠单抗和帕妥珠单抗治疗高危HER2阳性早期乳腺癌（DESTINY-Breast11）：一项随机、开放标签、多中心、III期临床试验

Annals of Oncology
IF65.4
2025-10-210
OAAI
Nadia Harbeck; Shanu Modi; Lajos Pusztai; Shinji Ohno; Jiong Wu; Sung-Bae Kim; Atsushi Yoshida; Alessandra Fabi; Xuchen Cao; Rona Joseph; Rubi Li; Bogdan Żurawski; Santiago Escrivá-de-Romaní; Renata Meneguetti; Archara Supavavej; Shin-Cheh Chen; Zhenzhen Liu; Catherine Kelly; Giuseppe Curigliano; William F. Symmans; Mohammad Gufran; Jun Ke; Adam Konpa; Pia Herbolsheimer; Jean-François Boileau
The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours

SPAG6的两面性：在乳腺肿瘤中SPAG6表达广泛缺失的背景下，诱导乳腺导管癌细胞发生EMT

Journal of Cellular and Molecular Medicine
IF4.2
2025-10-090
OAAI
Antonio Sechi; Jolein Mijnes; Sophia Villwock; Michael Rose; Florian Steib; Sarah Bringezu; Jonas Berger; Carmen Schalla; Sonja von Serenyi; Jana Dietrich; Nadina Ortiz-Brüchle; Lara Heij; Jan Bednarsch; Oleg Gluz; Ulrike Nitz; Nadia Harbeck; Monika Graeser; Christine zu Eulenburg; Mohammad Parsa Mohammadian; Katarzyna Jóźwiak; Hans-Heinrich Kreipe; Matthias Christgen; Martin Radner; Danny Jonigk; Edgar Dahl
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

曲妥珠单抗德鲁替康在HER2低表达转移性乳腺癌中的应用：DESTINY-Breast04随机三期试验的长期生存分析

Nature Medicine
IF50
2025-10-080
OAAI
Shanu Modi; William Jacot; Hiroji Iwata; Yeon Hee Park; Maria Vidal Losada; Wei Li; Junji Tsurutani; Naoto T. Ueno; Khalil Zaman; Aleix Prat; Konstantinos Papazisis; Hope S. Rugo; Toshinari Yamashita; Nadia Harbeck; Seock-Ah Im; Michelino De Laurentiis; Jean-Yves Pierga; Xiaojia Wang; Andrea Gombos; Eriko Tokunaga; Cecilia Orbegoso Aguilar; Lotus Yung; Feng Xiao; Yingkai Cheng; David Cameron
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

潜在生物标志物与接受帕博利珠单抗或化疗治疗的转移性三阴性乳腺癌患者临床结局的关联

npj Breast Cancer
IF7.6
2025-10-020
OA
Javier Cortes; Oleg Lipatov; Seock-Ah Im; Anthony Goncalves; Keun Seok Lee; Peter Schmid; Kenji Tamura; Laura Testa; Shoichiro Ohtani; Nadia Harbeck; Sherene Loi; Roberto Salgado; Vassiliki Karantza; Jaime Mejia; Razvan Cristescu; Andrey Loboda; Michael Nebozhyn; Petar Jelinic; Lingkang Huang; Eric P. Winer
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders

一个预测性内分泌抵抗指数能够准确地对腔面型乳腺癌治疗反应者和非反应者进行分层。

JOURNAL OF CLINICAL INVESTIGATION
IF13.6
2025-10-012
OA
Zhang, Guokun; Jurinovic, Vindi; Bartels, Stephan; Christgen, Matthias; Christgen, Henriette; Kandt, Leonie Donata; Mishieva, Lidiya; Ni, Hua; Raap, Mieke; Klein, Janin; Katzke, Anna-Lena; Hofmann, Winfried; Steinemann, Doris; Kates, Ronald E.; Gluz, Oleg; Graeser, Monika; Kummel, Sherko; Nitz, Ulrike; Plass, Christoph; Lehmann, Ulrich; Eulenburg, Christine zu; Mansmann, Ulrich; Gerhauser, Clarissa; Harbeck, Nadia; Kreipe, Hans H.
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

预测年轻乳腺癌患者接受化疗和抗HER2治疗后卵巢功能丧失

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2025-09-013
OAAI
Lambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger P.; Harbeck, Nadia; Swain, Sandra M.; Geyer, Charles E.; Slamon, Dennis J.; Bobba, Gabriella; Lambertini, Chiara; de Haas, Sanne; Restuccia, Eleonora; Vaz-Luis, Ines; Cameron, David A.; Krop, Ian E.; Winer, Eric P.; Anderson, Richard A.

研究方向

暂未获取到该数据
R
Rachel Wuerstlein
H 指数:38论文数:475被引数:5,749
O
Oleg Gluz
H 指数:38论文数:417被引数:6,724
U
Ulrike Nitz
H 指数:39论文数:401被引数:1.3万
R
Ronald Kates
H 指数:42论文数:357被引数:6,721
J
Javier Cortés
H 指数:113论文数:1,480被引数:6.7万
M
Matthias Christgen
H 指数:38论文数:245被引数:5,349
F
Fátima Cardoso
H 指数:103论文数:824被引数:6.4万
M
Michael Braun
H 指数:46论文数:388被引数:8,311
G
Giuseppe Curigliano
H 指数:118论文数:1,728被引数:7.2万
C
Christoph Thomssen
H 指数:74论文数:831被引数:2.8万